From: Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer’s disease
Discovery | AmnAD | AtAD | Control |
---|---|---|---|
N | 42 | 17 | 133 |
Age (mean ± SD) | 76.2 ± 7.9 | 73.3 ± 6.5 | 73.9 ± 6.2 |
% Female | 42.9% | 41.2% | 57.1% |
Education (years, mean ± SD) | 16.3 ± 2.5 | 16.5 ± 2.9 | 17.3 ± 2.1 |
% APOE4 carrier | 64.3% | 41.2% | 20.3% |
Validation | AmnAD | AtAD | Control |
N | 84 | 22 | 150 |
Age (mean ± SD) | 80.7 ± 8.4 | 80.9 ± 9.3 | 76.8 ± 7.4 |
% Female | 53.6% | 27.3% | 53.3% |
Education (years, mean ± SD) | 15.8 ± 3.1 | 16.1 ± 4.8 | 17.4 ± 2.1 |
% APOE4 carrier | 49.4% | 36.4% | 24.0% |
Global | AmnAD | AtAD | Control |
N | 126 | 39 | 283 |
Age (mean ± SD) | 79.2 ± 8.5 | 77.6 ± 9.0 | 75.4 ± 7.0 |
% Female | 50.0% | 33.3% | 55.1% |
Education (years, mean ± SD) | 16.0 ± 2.9 | 16.7 ± 3.1 | 17.4 ± 2.1 |
% APOE4 carrier | 55.2% | 38.5% | 22.3% |